NNVC - NanoViricides, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc.

NNVC 1.660

-2.4%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: HardToFind who wrote (12782)	5/27/2020 7:31:43 AM
From: old 'n cranky	Read Replies (1) of 12871

I read the thing pretty carefully. My point was that NNVC says that they believe that "hCoV-NL63 serves as a useful model for drug development against SARS-CoV-2" because (note the "therefore" in the statement) its something that they can use in their lab, not because it is the most suitable model for drug development against SARS-CoV-2. Obviously if they couldn't study it it wouldn't be useful. But the fact that they CAN study it doesn't speak to how appropriate it is. When all of this plays out and the funds are used, flowing in the usual direction, and the phrase "but milder" comes up again, you'll grasp my point. It will have been the latest project that went nowhere. Ok, I'll admit to a heap of skepticism. If you can point me to just one project that has ended in a drug versus an explanation for why there wasn't one I'll get over it. youtube.com (not a big Who fan, but it seems to fit here nicely)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next